Home / Sweden / Oncopeptides AB
Oncopeptides AB
Short position disclosed on October 30, 2026.
1.48% of the capital sold short
2 disclosing funds
440 disclosures on record
SE0009414576 ISIN code
Evolution of the disclosed total
0%0.5%1%1.5%2%
2025-13-01Apr 2026Jul 2026Oct 2026
July 24, 2018 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| GSA Capital Partners LLP | 0.88% | new | October 19, 2026 | |
| Two Sigma Investments, LP | 0.60% | new | October 30, 2026 |
On the other side: the funds that hold Oncopeptides AB Titelia
Get the moves on Oncopeptides AB by mail, at most once a day.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
Download 440 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Sweden
- Samhällsbyggnadsbolaget i Norden AB 11.43% of the capital sold short
- JM AB 7.91% of the capital sold short
- Elekta AB (publ) 7.80% of the capital sold short
- Truecaller AB 6.94% of the capital sold short
- Intrum AB 6.22% of the capital sold short
- Mips AB 5.30% of the capital sold short
- Xvivo Perfusion Aktiebolag 5.11% of the capital sold short
- Cibus Real Estate AB (publ) 4.66% of the capital sold short
- Hemnet Group AB (publ) 4.59% of the capital sold short
- Aktiebolaget Electrolux 4.58% of the capital sold short
- Dynavox Group AB 4.31% of the capital sold short
- RaySearch Laboratories AB (publ) 4.07% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Oncopeptides AB, source Finansinspektionen, data as at October 30, 2026, https://www.quivad.com/action/oncopeptides-ab?page=3